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Abstract
Animal models for cancer therapy are invaluable for preclinical testing of potential cancer treatments; however,
therapies tested in such models often fail to translate into clinical settings. Therefore, a better preclinical model for
cancer treatment testing is needed. Here we demonstrate that an immunodeficient line of pigs can host and sup-
port the growth of xenografted human tumors and has the potential to be an effective animal model for cancer
therapy. Wild-type and immunodeficient pigs were injected subcutaneously in the left ear with humanmelanoma
cells (A375SM cells) and in the right ear with human pancreatic carcinoma cells (PANC-1). All immunodeficient
pigs developed tumors that were verified by histology and immunohistochemistry. Nonaffected littermates did
not develop tumors. Immunodeficient pigs, which do not reject xenografted human tumors, have the potential to
become an extremely useful animal model for cancer therapy because of their similarity in size, anatomy, and
physiology to humans.
Key words: immunodeficient swine; large-animal cancer model; melanoma; pancreatic carcinoma; xenografts
Background
Preclinical research on animal models is essential indeveloping and evaluating cancer therapeutics.1 Synge-
neic, xenograft, and genetically engineered mouse models
have been developed to study cancer and cancer drug devel-
opment.2 Mouse xenograft models are used extensively in
preclinical studies because of their relatively good correlation
with human clinical data, as compared to other animal mod-
els.3–5 However, studies on these mouse models often fail to
accurately predict the response to and the effect of anticancer
agents in human patients.3–5 Ninety percent of new antican-
cer drugs that showed antitumor efficacy in mouse-based
preclinical studies failed in human clinical studies.4,5 Several
methods of overcoming this shortfall have been proposed,
including genetically engineered transgenic mouse models
and orthotopic xenograft models,6,7 but these have yet to
demonstrate significant improvements in translatability.6
Thus, there is a tremendous demand for more sophisticated
animal models, which may improve the translation efficiency
from preclinical to clinical studies.
Pigs are large animals with similar anatomy and physiol-
ogy to humans and have been used in many research
areas.8 The higher sequence homology of pigs with human
xenobiotic receptors may allow more accurate prediction of
pharmacodynamic and pharmacokinetic properties of drugs
compared with mice.9 Several attempts have beenmade to es-
tablish porcine tumor models in pigs as a treatment model for
human cancers, for example, investigating spontaneous mye-
logenous leukemias,10 developing transplantable hemato-
logic tumors,11 and genetically inducing tumorigenesis.12
A xenograft model of human tumors in pigs would be an
excellent model. Xenograft models of human tumors are
often used in severe combined immunodeficiency (SCID)
mice, which have severe lymphopenia due to defects
in a DNA-dependent protein kinase gene that prevents
Departments of 1Anatomy and Physiology, 2Diagnostic Medicine and Pathobiology, 4Clinical Sciences, and 5Chemistry, Kansas State
University, Manhattan, Kansas.
3Department of Animal Science, Iowa State University, Ames, Iowa.
*These two authors contributed equally to this work and are co-first authors.
BioResearch Open Access
Volume 1, Number 2, 2012
ª Mary Ann Liebert, Inc.
DOI: 10.1089/biores.2012.9902
63
variable–diversity–joining [V(D)J] gene region recombina-
tion.13 The severe lymphopenia prevents SCID mice from
rejecting human tumors. SCID-associated severe lymphope-
nia is also known in other species, notably humans. Several
genetic defects have been identified in humans as causing
SCID, including defects in adenylate kinase 2, adenosine de-
aminase, purine nucleoside phosphorylase, interleukin (IL)-2
receptor c, Janus kinase 3, and the IL-7 receptor.14 We recently
identified pigs that are severely immunocompromised (SCID-
like pigs).15 Yorkshire pigs bred for increased feed efficiency
were noted to exhibit SCID-like symptoms. Further analysis
of these pigs showed extremely decreased levels of lympho-
cytes in circulation and significantly atrophied thymus and
lymph nodes. The mode of inheritance appears to be simple
autosomal recessive, although the actual mutation remains
to be elucidated. In the present study, we show evidence
that these pigs can be used as human xenograft tumor mod-
els. As proof of concept, human melanoma cells (A375SM,
amelanotic melanoma) and human pancreatic carcinoma
cells (PANC-1) were transplanted subcutaneously into immu-
nodeficient pigs, and the tumor-forming ability of the neo-
plastic cells was evaluated.
Methods
Reagents and cells
PANC-1 cells and A375SM cells were purchased from
ATCC (Manassas, VA). Dulbecco’s Modified Eagle’s Medium
(DMEM) and penicillin (10,000 units/mL)/streptomycin
(10,000lg/mL) were purchased from Life Technologies
(Grand Island, NY). Fetal bovine serum (FBS), hematoxylin,
eosin, Tris–hydrochloride, and ethylenediaminetetraacetic
acid (EDTA) were purchased from Sigma-Aldrich (St. Louis,
MO). Antimitochondrial clone 113-1 (mouse anti-human mi-
tochondrial antibody) was purchased from Millipore (Teme-
cula, CA). Bond Polymer Refine Red detection kit, Bond
Primary Antibody Diluent, and alkaline phosphatase-conju-
gated Poly-AP anti-mouse antibody were purchased from
Leica Microsystems (Buffalo Grove, IL). Fatal-plus (pentobar-
bital sodium) was obtained from Vortech Pharmaceuticals
(Dearborn, MI). Banamine (flunixin meglumine) was
obtained from Merck Animal Health/Intervet (Summit, NJ).
Excenel (ceftiofur HCl) was obtained from Pfizer Animal
Health (New York, NY). Second Bite Medicated feed with
Tiamulin (35 g/ton) and chlortetracycline (400 g/ton) was
purchased from Key Feeds, Fourth and Pomeroy Associates
(Clay Center, KS).
Pig care
Six littermate pigs (6 weeks of age, two male and four fe-
male) were obtained from Iowa State University from a
boar and a sow that have been identified as carriers of the im-
munodeficiency gene. Pigs were identified at 2 weeks of age
as likely to be immunodeficient or immunocompetent based
on lymphocyte counts: values were 1.08, 1.22, and 1.81 · 103
lymphocytes/lL for pigs expected to be immunodeficient
(n = 3, one male, two female) and 3.08, 4.13, and 5.18 · 103
lymphocytes/lL for presumed immunocompetent pigs
(n = 3, one male, two female). Pigs were transported to the
Kansas State University at 6 weeks of age. Pigs were housed
in a clean environment in raised pens upon arrival; however,
neither the previous housing nor transportation was aseptic.
Two days after arrival, blood samples were collected from the
pigs to confirm the status of each pig by immunophenotyp-
ing. After confirmation of the immune status, the immunode-
ficient pigs were separated from the immunocompetent pigs
in two different rooms in a clean environment in raised pens.
Pigs were kept on a medicated diet and monitored daily for
health status; ceftiofur HCl (2.2mg/kg) and flunixin meglu-
mine (1.1mg/kg) were administered intramuscularly as indi-
cated by veterinary consultation.
Xenograft tumor injection
A375SM cells and PANC-1 cells were cultured in the
DMEM with 10% FBS and 1% penicillin/streptomycin.
PANC-1 and A375SM cells were lifted, counted, and concen-
trated to 40 million cells/mL in PBS. Pigs were anesthetized
by administration of isoflurane gas vaporized into oxygen
(1–5%) and delivered via a face mask. 100lL (4 million
cells) of the PANC-1 cell suspension was injected subcutane-
ously into the right ear by tenting the skin of the ear near the
base; 100lL (4 million cells) of the A375SM cell suspension
was injected subcutaneously into the left ear by tenting the
skin of the ear near the base. After injecting, the pigs were re-
moved from anesthesia and observed until reaching sternal
recumbency.
After tumor injection, the pigs were monitored daily for
tumor growth. Both right and left ears were visually
inspected and palpated to determine presence of tumors
daily. Once tumors were identified, calipers were used to
measure the tumor size.
Histopathology and immunohistochemistry
Immunocompromised pigs were monitored for signs of
respiratory disease, which often occurs because of the im-
munocompromised status. When a serious disease pre-
sented, the pigs were euthanized using Fatal-plus (days
6, 14, and 22). Unaffected littermates were euthanized
with the last immunocompromised pig at day 22. At eutha-
nasia, ear tissue was collected and fixed in 10% buffered
formalin, processed routinely for sectioning, and then
stained with hematoxylin and eosin (H&E). H&E sections
were evaluated for histological evidence of tumors. For im-
munohistochemical analysis, unstained paraffin-embed-
ded tissue was probed with anti-human mitochondrial
antibody. Tissues were stained using the Leica Bond-Max
automatic stainer (Leica Microsystems) with the Bond Pol-
ymer Refine Red detection kit. Tissues were pretreated for
20min with Tris–EDTA (pH 9.0) for antigen retrieval. The
primary antibody was diluted 1:100 using Bond Primary
Antibody Diluent. Tissues were then stained with the pri-
mary antibody for 15min followed by a secondary anti-
body (Powervision Poly-AP Anti-Mouse) for 25min.
Antibody-probed tissues were then counterstained with
hematoxylin. Antibody-probed sections were evaluated
for positive staining, indicating the presence of human
cells.
Results
Pig observations
No visible tumor growth was noted at day 6 when the first
immunodeficient pig (pig 1) was euthanized. On day 13, a
64 BASEL ET AL.
small, firm, very slightly raised, elongated white mass was
identified visually and by palpation on the left ear (amela-
notic melanoma) of pig 2, but was too small to measure
with the caliper. Pig 2 was euthanized on day 14. On day
14, a similar small, firm, raised, elongated white mass was
identified on the left ear of pig 3, but was too small to mea-
sure with the caliper. On day 20, gross photographs were
taken of the mass (Fig. 1). On day 22, pig 3 was euthanized.
At postmortem examination, the tumor in the left ear (mela-
noma) was dissected free from the skin and measured
10.3 · 5.5mm. No grossly discernible tumors were observed
in the right ears (pancreatic carcinoma) of any of the immuno-
deficient pigs. No grossly discernible tumors were observed
in either ear in the wild-type pigs.
Histopathology and immunohistochemistry
Histology and immunohistochemistry revealed the pres-
ence of tumors in all injection sites for both tumors in SCID-
like pigs. Pig 1 showed small tumors in both the right ear
(Fig. 2A) and the left ear (Fig. 3A) histologically, indicating
the lack of rejection of both the PANC-1 and the ASM375
cells. These tumors were verified by strong positive cytoplas-
mic staining with anti-human mitochondrial antibody (Figs.
FIG. 1. Antemortem visual evidence
of tumor growth in pig 3 (day 20). (A)
Photograph indicates a large growth
on the left ear. (B) Same photograph as
in (A), with the growth outlined for
visual reference.
FIG. 2. Right ear with pancreatic carcinoma cells from pigs euthanized at day 6, 14, and 22 post-transplantation. (A) There is
a focal, well-demarcated, unencapsulated neoplasm composed of nests and packets of neoplastic cells within the subcutis. (B,
C) Strong positivity to anti-human mitochondrial antibody is evident within the cytoplasm of neoplastic cells. (D)Within the
subcutis and skeletal muscle, there is an unencapsulated, moderately demarcated, and mildly infiltrative neoplasm composed
of nests and packets of neoplastic cells. (E, F) Strong positivity to anti-human mitochondrial antibody is evident within the
cytoplasm of neoplastic cells. (G)Within the dermis, subcutis, and skeletal muscle, there is an unencapsulated, poorly demar-
cated, and infiltrative neoplasm composed of nests and packets of neoplastic cells. (H, I) Strong positivity to anti-human mi-
tochondrial antibody is evident within the cytoplasm of neoplastic cells. (A, D, G) H&E stain; (B, C, E, F, H, I) anti-human
mitochondrial antibody immunohistochemistry. H&E, hematoxylin and eosin.
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2B, C and 3B, C). Pig 2 also showed tumors in both the right
ear (Fig. 2D) and the left ear (Fig. 3D) histologically, which
were verified by positive immunostaining (Figs. 2E, F and
3E, F). Pig 3 also showed tumors in both the right ear and
the left ear that were substantially larger than the tumors of
pigs 1 and 2. These tumors were also identified histologically
and verified by positive staining with anti-human mitochon-
drial antibody (Figs. 2G–I and 3G–I).
All six tumor sites showed characteristic histologic fea-
tures of malignant neoplasia, including bizarre and atypi-
cal mitotic figures and prominent anisocytosis and
anisokaryosis (Fig. 4). Full histopathological descriptions of
the tumors of each immunodeficient pig are found in the Sup-
plementary Data. No tumors were identified histologically in
the ears of wild-type pigs (Fig. 5), consistent with expected
rejection of human origin cells by pigs with intact immune
systems.
Discussion
A large-animal model of human tumors that closely mim-
ics the size, anatomy, and physiology of humans would be of
FIG. 3. Left ear with melanoma cells from pigs euthanized at day 6, 14, and 22 post-transplantation. (A)Within the deep der-
mis, subcutis, and skeletal muscle, there is an unencapsulated and infiltrative neoplasm composed of nests and short streams of
neoplastic cells. (B, C) Strong positivity to anti-humanmitochondrial antibody is evident within the cytoplasm of neoplastic cells.
(D) Within the deep dermis and subcutis, there is an unencapsulated and infiltrative neoplasm composed of nests and short
streams of neoplastic cells within a moderate amount of fibrovascular stroma. (E, F) Strong positivity to anti-human mitochon-
drial antibody is evident within the cytoplasm of neoplastic cells. (G)Within the deep dermis and subcutis, there is an unencap-
sulated, moderately demarcated, and infiltrative neoplasm composed of nests and short streams of neoplastic cells within a
moderate amount of fibrovascular stroma. (H, I) Strong positivity to anti-human mitochondrial antibody is evident within the
cytoplasm of neoplastic cells. (A, D, G)H&E stain; (B, C, E, F, H, I) anti-human mitochondrial antibody immunohistochemistry.
FIG. 4. Photomicrographs of the left
ear of pig 3 demonstrating histologic
features of neoplasia. (A)Note multiple
mitotic figures. (B) Note significant
cellular and nuclear pleomorphism.
H&E stain.
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great value to cancer research. Here we have demonstrated
that a naturally occurring immunodeficient line of pigs is ca-
pable of hosting xenograft human cells and developing active
human tumors. It is possible that immunodeficient pigs fail to
reject human xenograft tumors due to their low levels of lym-
phocytes, but immunodeficient pigs do not fail to produce all
lymphocytes. Preliminary results indicate that the lympho-
cytes present in immunodeficient pigs do not express CD3,
CD4, CD8, CD21, or CD79a. This may indicate that the
remaining cells are natural killer (NK) cells that may not be
functional due to lack of T-cell-associated cytokine stimula-
tion. Therefore, there may be no functional lymphocytes
that would be able to reject the human tumor xenograft. Fur-
ther studies are being done on the lymphocyte profiles in the
immunodeficient pigs.
The melanomamodel described here is orthotopic; the sub-
cutaneous model of pancreatic adenocarcinoma, however, is
not orthotopic. For this study, the proof of concept that im-
munodeficient pigs would not reject tumors was demon-
strated using an easily monitored tumor location. In the
future, orthotopic models of pancreatic cancer may be ex-
plored in these pigs to determine their suitability for investi-
gating this devastating human cancer.
One of the major problems with current animal models for
human tumors is the low translatability to clinical settings.4
This is often due to the limited similarity in anatomy and
physiology of common tumor models such as SCID mice.3,4
Because pig anatomy and physiology are very similar to
that of humans, the immunodeficient pig tumor model
could be used for testing multiple types of cancer therapy, in-
cluding chemotherapy, radiotherapy, and surgical reduction,
with more realistic results. Therefore, this model has the po-
tential to be a valuable human cancer model for preclinical
cancer research, with a high rate of translatability to the clin-
ical settings.
The usefulness of this model may not be limited to cancer
therapy. Since the immunodeficient pigs do not reject xeno-
grafts, they may be a useful model for other disease states
as well. For example, human liver cell xenografts could be
grown in pigs and then infected with hepatitis B or C for test-
ing various antiviral medications. Similarly, the pigs could be
reconstituted with primitive human hematopoietic stem cells
(e.g., cord blood) to generate a pig chimera with a human im-
mune system, a useful model for studies such as human im-
munodeficiency virus antiviral therapies. Thus, a pig model
that does not reject human xenografts is a unique animal
model with potential uses in a variety of preclinical applica-
tions for human health.
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